Evidence map›Paper›PMID 28481909›Full record

ArticlePloS one2017

The thyroid cancer policy model: A mathematical simulation model of papillary thyroid carcinoma in The U.S. population.

Carrie Lubitz, Ayman Ali, Tiannan Zhan, Curtis Heberle, Craig White, Yasuhiro Ito, Akira Miyauchi, G Scott Gazelle, Chung Yin Kong, Chin Hur

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. A Scoping Review on Calibration Methods for Cancer Simulation Models.Medical decision making : an international journal of the Society for Medical Decision Making · 2025
    Article
  2. Article
  3. Modeling Thyroid Cancer Epidemiology in the United States Using Papillary Thyroid Carcinoma Microsimulation Model.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2024
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Carrie LubitzInstitute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts, United States of America.ORCID http://orcid.org/0000-0002-6786-5477
Ayman AliInstitute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Tiannan ZhanInstitute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Curtis HeberleInstitute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Craig WhitePhD Program in Health Policy, Graduate School of Arts and Sciences, Harvard University, Cambridge, Massachusetts, United States of America.
Yasuhiro ItoDepartment of Surgery, Kuma Hospital, Kobe, Japan.
Akira MiyauchiDepartment of Surgery, Kuma Hospital, Kobe, Japan.
G Scott GazelleHarvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Chung Yin KongInstitute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Chin HurInstitute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Harvard University · USMassachusetts General Hospital · USKuma Hospital · JP

Funding

Optimization of Treatment of Papillary Thyroid Cancer: A Risk-tailored ApproachK07CA177900 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CUNNINGHAM, CARRIE ELIZABETH · 2014 to 2018
$712k
NCI NIH HHS K07 CA177900
6 · The paper itself

Abstract

backgroundThyroid cancer affects over ½ million people in the U.S. and the incidence of thyroid cancer has increased worldwide at a rate higher than any other cancer, while survival has remained largely unchanged. The aim of this research was to develop, calibrate and verify a mathematical disease model to simulate the natural history of papillary thyroid cancer, which will serve as a platform to assess the effectiveness of clinical and cancer control interventions.

methodsHerein, we modeled the natural pre-clinical course of both benign and malignant thyroid nodules with biologically relevant health states from normal to detected nodule. Using established calibration techniques, optimal parameter sets for tumor growth characteristics, development rate, and detection rate were used to fit Surveillance Epidemiology and End Results (SEER) incidence data and other calibration targets.

resultsModel outputs compared to calibration targets demonstrating sufficient calibration fit and model validation are presented including primary targets of SEER incidence data and size distribution at detection of malignancy. Additionally, we show the predicted underlying benign and malignant prevalence of nodules in the population, the probability of detection based on size of nodule, and estimates of growth over time in both benign and malignant nodules.

conclusionsThis comprehensive model provides a dynamic platform employable for future comparative effectiveness research. Future model analyses will test and assess various clinical management strategies to improve patient outcomes related to thyroid cancer and optimize resource utilization for patients with thyroid nodules.

Indexed as

Models, TheoreticalCarcinomaCarcinoma, PapillaryHumansThyroid Cancer, PapillaryThyroid NeoplasmsUnited States

Identifiers

PMID28481909
PMCPMC5421766
OpenAlexW2613858008

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.